The clinical trial compares laparoscopic sleeve gastrectomy (LSG) with metformin in treating obese patients with PCOS, a condition affecting 5% to 15% of premenopausal women. Given the rising prevalence of obesity and metabolic disorders, successful outcomes could position LSG as a viable alternative to pharmacological treatments, potentially expanding market share in obesity management. The trial's findings may influence clinical guidelines and treatment paradigms, enhancing the competitive landscape for surgical interventions in metabolic disorders. Stakeholders should monitor the trial's progress and results for implications on reimbursement and market access strategies.